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Aim Experimental animal studies suggest that the use of skeletal myoblast in patients
with myocardial infarction may result in improved cardiac function. The aim of the
study was to assess the feasibility and safety of this therapy in patients with
myocardial infarction.
Methods and results Twelve patients with old myocardial infarction and ischaemic
coronary artery disease underwent treatment with coronary artery bypass surgery and
intramyocardial injection of autologous skeletal myoblasts obtained from a muscle
biopsy of vastus lateralis and cultured with autologous serum for 3 weeks. Global and
regional cardiac function was assessed by 2D and ABD echocardiogram. 18F-FDG and
13N-ammonia PET studies were used to determine perfusion and viability. Left
ventricular ejection fraction (LVEF) improved from 35.5±2.3% before surgery to
53.5±4.98% at 3 months (P=0.002). Echocardiography revealed a marked improvement
in regional contractility in those cardiac segments treated with skeletal myoblast
(wall motion score index 2.64±0.13 at baseline vs 1.64±0.16 at 3 months P=0.0001).
Quantitative 18F-FDG PET studies showed a significant (P=0.012) increased in cardiac
viability in the infarct zone 3 months after surgery. No statistically significant
differences were found in 13N-ammonia PET studies. Skeletal myoblast implant was
not associated with an increase in adverse events. No cardiac arrhythmias were
detected during early follow-up.
Conclusions In patients with old myocardial infarction, treatment with skeletal
myoblast in conjunction with coronary artery bypass is safe and feasible and
is associated with an increased global and regional left ventricular function,
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improvement in the viability of cardiac tissue in the infarct area and no induction of
arrhythmias.
© 2003 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.
Introduction
Myocardial infarction (MI) is associated with loss and
dysfunction of cardiomyocytes and leads to heart failure
and death as a consequence of irreversible cell loss.
Unlike other tissues, the heart muscle has a very limited
if any, capacity of regeneration. Lack of stem cells in the
heart and potential of the damaged heart cells to
undergo repair or divide at least to a significant extent
are the main reasons for this inability.1,2 Medical treat-
ment or revascularization can improve the function of
viable or hibernating myocardium, but cannot restore
necrotic myocardial tissue.
Cellular transplantation has emerged as a potential
alternative to heart transplant for patients with end-
stage cardiac disease.3,4 With the aim of replacing
necrotic tissue, cells from different sources have been
implanted in animal models of myocardial infarction
including embryonic stem cells,5 fetal cardiomyocytes,6
skeletal myoblast,7 haematopoietic stem cells,8 mesen-
chymal stem cells9 or endothelial progenitor cells.10 Most
of these studies have invariably shown engraftment of
donor cells and reconstitution of heart structures, i.e.,
cardiomyocytes and blood vessels, and most of them
have been associated with improved heart function.
Recently, the results from clinical trials of intramyocar-
dial cell transplantation with bone marrow mononuclear
cells (BMMNC)11,12 or bone marrow derived AC133 posi-
tive cells13 for cardiac regeneration have been reported.
Injection of skeletal myoblast in animal models of
myocardial infarction and more recently in humans
has been associated with successful engraftment of
skeletal muscle fibers, graft survival and functional
benefit.7,14–22 Although controversial, some evidences
suggest that skeletal muscle progenitors may acquire
certain characteristics of cardiac muscle both in vitro and
in vivo.19,22–24
We have examined, in a phase I clinical study, the
feasibility and safety of intramyocardial transplantation
of autologous skeletal myoblast cultured in vitro with
autologous serum in patients with old myocardial infarc-
tion undergoing coronary artery bypass surgery. Our
results show that the procedure is safe and feasible.
Furthermore, functional as well as viability studies sug-
gest that the combination of bypass surgery with implan-
tation of autologous skeletal myoblast is associated with
improvement in cardiac contractility and viability of the
scarred tissue.
Patients and methods
Patient population and study design
A total of 12 patients were included in the study. Inclusion
criteria were: (1) >4 weeks previous history of myocardial infarc-
tion with an akinetic or dyskinetic non viable scar, as demon-
strated by lack of metabolic activity on fluorine-18
fluorodeoxyglucose (18F-FDG) positron emission tomography
(PET); (2) indication for coronary artery bypass graft (CABG);
(3) age 30–80; and (4) left ventricular ejection fraction greater
than 25%. Exclusion criteria included (1) inability to obtain a
myoblast cell culture; (2) positive serologic test for HIV or
hepatitis; (3) previous history of malignant arrhythmias or
muscular dystrophy; and (4) abnormal liver or kidney function
test. The protocol and all the procedures were approved by the
Institutional Review Board for Human Studies and Ethics Com-
mittee, the Regional Review Board for Clinical Trials with Human
Subjects and the Spanish Health Authorities. All patients signed
an informed consent before entering the study.
Baseline studies
Before surgery all patients underwent 13N-ammonia and 18F-FDG
positron emission tomography scan, echocardiogram and 24 h
Holter-ECG to determine function and viability of the heart
muscle. Laboratory studies included cardiac and liver enzymes.
Echocardiographic studies
Global and regional myocardial contractility were measured by
two dimensional echocardiography using a Sonos 5500 ultra-
sound system (Philips). Regional left ventricular wall motion
analysis was performed as described by the committee on
Standards of the American Society of Echocardiography,25
dividing the left ventricle into 16 segments and scoring wall
motion as 1=normal, 2=hypokinesis, 3=akinesis, 4=dyskinesis for
each segment. The wall motion score index (WMSI) was calcu-
lated as the sum of the scores of the segments divided by the
number of segments evaluated. WMSI was calculated for seg-
ments treated and non-treated with cell implant. Left ventricu-
lar ejection fraction (LVEF) was also calculated by using
automatic border detection system (ABD).26 Regional contractil-
ity was also assessed by colour-kinesis and tissue-Doppler for
each segment. All studies were performed by two different
observers blinded to clinical data. Reproducibility values
within studies were 2.8±6.4 ml (CV 5.5%) for left ventricular
end-diastolic volume and 0.3±4.6 (CV 6.6%) for LVEF.
Positron emission tomography studies
Myocardial blood flow and glucose metabolism were measured
by PET scans before treatment. The perfusion and metabolism
studies were performed with a whole-body positron emission
tomograph (Siemens/CTI ECAT EXACT HR+, Knoxville, USA)
which acquires 63 transaxial planes with an interplane spatial
resolution of 4.5 mm. The 18F-FDG and 13N-ammonia were pro-
duced by in-site cyclotron (Cyclone 18/9, Ion Beam Applications,
Belgium) and the radiopharmaceutical processing equipment.
Image acquisition: Before each study, a 2-min transmission
scan was used to position the heart within the field of view,
followed by a 5-min transaxial transmission scan using
germanium-68 line sources to measure the photon attenuation
correction. Intravenous injection of 13N-ammonia (9.25 MBq per
kg, maximum 740 MBq) was slowly infused at a constant rate of
10 ml/min and acquisition was started at the beginning of the
injection. Serial images were acquired for 20 min in a dynamic
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sequence with varying frame duration (12×10 s, 4×15 s, 4×30 s,
3×300 s). This protocol has been previously described by Muzic
et al.27 After acquisition of the 13N-ammonia study, a period of
50 min was allowed for the physical decay of the 13N-ammonia
radioactivity (physical half-life 9.9 min).
The glucose metabolic studies were performed using the
hyperinsulinemic-euglycaemic clamp technique which allows to
differentiate inflammation.28 18F-FDG was injected as an intra-
venous bolus after stabilization of the glucose level between 85
and 95 mg/dl (4.6 MBq per kg, maximum 370 MBq). The acquisi-
tion of the 18F-FDG images started at the injection time and
serial images were recorded for 60 min (8×15 s, 2×30 s, 2×120 s,
1×180 s, 4×300 s, 3×600 s), according to Knuuti et al.28
Image processing: The reconstructed transmission images
were segmented prior to their utilization in the attenuation
correction of the emission data sets. The frames of the meta-
bolic study were reconstructed using ordered subsets expec-
tation maximization (OSEM) with two iterations and eight
subsets. A Gaussian smoothing filter of 6 mm FWHM was applied.
The transaxial images were reoriented in left ventricular short-
axis, vertical long axis and horizontal long axis views for visual
analysis. Six contiguous short-axis cross sections of the mid left
ventricle were used for quantitative analysis. Tracer uptake was
calculated for different regions and a quantitative absolute
numerical value were assigned Regional myocardial blood flow
(MBF) was calculated according to a three-compartment
model,29 and Patlak graphical analysis was applied to estimate
regional myocardial glucose utilization rates (rMGU) from 18F-
FDG PET data glucose utilization.28
Autologous skeletal myoblast cell culture
Three weeks before CABG surgery a muscle biopsy was obtained
from the vastus lateralis under sterile conditions and local
anaesthesia (2% lidocaine hydrochloride) and processed immedi-
ately to obtain muscle progenitor cells as described with modi-
fications.7 Briefly, muscle biopsy was stripped of connective
tissue, minced and digested with trypsin/EDTA (0.5 mg/ml
trypsin and 0.53 mm EDTA, GIBCO-BRL) and collagenase
(0.5 mg/ml, GIBCO-BRL) to release satellite cells. After filter-
ing, cells were grown in 79% Ham-F12 media (GIBCO-BRL) sup-
plemented with 20% autologous serum and 1% penicillin/
streptomycin (GIBCO-BRL). All patients underwent a plasma
exchange the day before muscle biopsy using heparine as anti-
coagulant. Coagulation proteins were eliminated by neutraliz-
ation of heparin with protamine sulphate. After testing for
bacterial contamination, aliquots of 50 ml were cryopreserved
until usage. Cell cultures were incubated at 37°C and 5% CO2 and
passage of the culture was performed at sub-confluence to
prevent myotube formation. During the first passage, pre-
plating was applied to eliminate contamination of myoblasts
with fibroblasts. Myoblasts were harvested after 3–4 passages
for implantation. Myoblast purity was measured by flow cytom-
etry and staining with monoclonal antibodies against human
N-CAM (CD56), CD45 and desmin. These culture conditions
proved to be equivalent to the use of fetal calf serum in terms of
muscle progenitor yield and purity (data not shown). Myoblast
and muscle progenitor cells are CD56 positive, desmin positive,
CD45 negative.17,30
CABG surgery and cell implantation
Three to 4 weeks after muscle biopsy all patients underwent
conventional aortocoronary bypass surgery. During cardiopulmo-
nary bypass surgery, after all graft sutures had been finalized
immediately before removing extracorporeal circulation and
while the heart was initiating spontaneous heartbeat, muscle
progenitor cells (myoblast) were injected subepicardially by
multiple injections with an angled needle (Steriseal Ophthalmic
canula 23G, Maersk Medical Ltd. Redditch, B98 9NL GB) that
allows tangential injection of cells under the epicardium. Myo-
blasts were implanted in those segments previously identified by
echocardiography as akinetic or dyskinetic in and around the
infarct. Areas receiving cells were identified before surgery by
echocardiogram and these same areas were analyzed during
follow-up to determine changes in regional contractility. Before
proceeding to myoblast implantation a sample of the harvested
myoblasts was used for microbiology cultures, including gram
staining to determine culture contamination.
Follow-up procedures
After surgery and before discharge, patients were monitored
with continuous telemetry. Cardiac enzymes were analysed
every 6 h during patient hospitalization. Inflammation was moni-
tored by measuring the serum levels of C-reactive protein. All
patients received a dose of methylprednisolone of 500 mg after
surgery to prevent inflammation of the myocardium and oral
amiodarone for 3 months to prevent cardiac arrhythmias.
Outpatient follow-up included 13N-ammonia and 18F-FDG PET
3 months after surgery and echocardiogram 40 days and
3 months after surgery for assessment of cardiac function. The
presence of arrhythmias was monitored by Holter-ECG 40 days
and 3 months after CABG.
Statistical analysis
Statistical analysis was performed with the SPSS 10.0 for
windows software package. Comparisons were performed using
the paired t-test, Wilcoxon rank-sum test, ANOVA for repeated
measurements or Friedman test depending on the Shapiro–Wilk
and Kolmogorov–Smirnov normality test. Descriptive analysis is
presented as mean (SEM) for quantitative variables or median
(IQR) for categorical variables. Statistical significance was
achieved if P values were less than 0.05.
Results
The demographic, clinical and functional characteristics
of patients are included in Table 1. Mean follow-up for all
patients was 6.5 months (1.27). Initial therapy for acute
MI included fibrinolysis in seven patients, one primary
angioplasty and one differed angioplasty. Three patients
were managed with conservative treatment. Differences
in therapy are explained by the differences in standard
treatment according to the time when each patient was
treated for the acute MI.
Bypass surgery and cell transplantation
Patients were treated with bypass surgery and skeletal
myoblast transplant. Revascularization was based not on
the existence of tissue with residual viability but rather
on clinical data suggesting that moderate improvement
in a low percentage of non viable segments can be
obtained with revascularization. Revascularization
involved both areas with infarct and areas with viable or
hibernating tissue.
The median number of grafts was 2 (3). Revascular-
ization to areas of cell implantation was performed in all
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Table 1 Characteristics of the patientsa
Patient Age Sex MI location MI age
(months)
Symptoms
angina
NYHA baseline/
FU
Bypass
location
Muscle
biopsy
Myoblast
implanted
LVEF baseline 2D/
ABD
LVEF FU 2D/
ABD
1 63 M Anterior 4 Unstable III/II LAD, RC OM 10 g 318 35/37 55/56
2 64 M Anterior-apical 6 III II/I LAD, OM 13 g 165 40/45 50/53
3 40 M Inferior 5 Unstable II/I RC, LAD 7.5 g 192 45/46 70/65
4 55 M Anterior 23 I II/I LAD, RCOM 7 g 393 40/47 62/66
5 68 M Anterior-apical 168 III III/II LAD, RCOM 10 g 200 27/26 40/50
6 74 F Anterior 10 Unstable III/III LAD 9 g 110 30/38 40/48
7 69 M Inferior 125 Unstable II/no FU LAD, RC, OM, Dg 9.5 g 171 40/38 No FU
8 71 M Inferior 108 Unstable II/I LAD, OM 5.5 g 105 40/42 47/51
9 56 M Anterior 120 III I/I LAD, Dg OM 9 g 0 45/40 35/38
10 74 M Inferior 20 III II/no FU LAD, OM, Dg, RC 14 g 390 25/29 No FU
11 68 M Anterior 3 I I/I LAD, RC, OM 10 g 100 40/43 51/49
12 73 M Anterior-apical 146 III III/II LAD, Dg, OM 11.3 g 180 43/41 46/45
aAbbreviations: MI=myocardial infarction; NYHA=New York Heart Association; FU=follow-up assessment was considered 3 months after surgery; LAD=left anterior descendent coronary artery; RC=right coronary
artery; OM=obtuse marginal branch; Dg=diagonal coronary artery; Myoblast implant=number of cells×106; LVEF=left ventricular ejection fraction; 2D=bidimensional; ABD=automatic border detection.
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but one patient. Those cardiac segments akinetic and
dyskinetic received both revascularization and cell
implant while revascularization was the only treatment
for the other myocardial segments.
The mean size of the muscle biopsy was 9.45 g (0.81 g)
and the mean volume of autologous serum obtained was
1.735 ml (327.5 ml). After a median of 23 (15) days in
culture, a mean of 221×106 (100.37×106) myoblast were
obtained with a purity of 65.6% (18.2%) (percentage of
CD56 positive cells/CD45 negative cells. An average of
5 ml (3.5 to 6 ml) of solution containing skeletal myoblast
was injected by multiple injections as described in
methods. The average concentration of myoblast was
50×106 cells/ml and the number of injections varied
between 5 and 15. Besides the 12 patients receiving
skeletal myoblast, two further patients underwent a
muscle biopsy but could not receive cells due to the
inability of myoblasts to grow in culture. These patients
were not included in the study as determined in the
exclusion criteria.
Adverse events
Plasma exchange was not associated with adverse events
which is consistent with the fact that at a given time the
total extra vascular volume in the apheresis circuit was
less than 170 ml. All patients were discharged from the
hospital and are alive at the time of this report. The
median number of hospitalization days was 9 (3) and
the mean duration of extracorporeal circulation was
156 min (55 min). Myocardial inflammation due to the
procedure was indirectly assessed by measuring the
levels of C-reactive protein which were not significantly
different from baseline at 40 days and 3 months follow-up
(data not shown).
Patient 9 could not receive the myoblast implant
because a positive gram staining was detected immedi-
ately before implantation. This patient underwent all
protocol scheduled studies during the follow-up.
No ventricular tachyarrhythmias were detected after
treatment with bypass surgery and skeletal myoblast
implant during the hospitalization period or during out-
patient follow-up. The median number of premature
ventricular beats was 16 (393) and 6 (19) at baseline, post
surgery and at 3 months follow-up respectively (P=ns).
Placement of automatic internal cardioverter-
defibrillator was not required in any of our patients.
However, patient 6 developed a non-sustained ventricu-
lar tachycardia 40 days after surgery. In this patient
aneurysmectomy with the Dor technique had also been
performed.
Left ventricular function
Left ventricular ejection fraction (mean±SEM) was
increased from 35.5±2.3% before surgery to 53.5±4.98%
at 3 months (P=0.002) calculated by 2D echocardiography
and from 39.8±3.26% before surgery to 56.3±3.1%
(P=0.001) by ABD calculation (Fig. 1). The median
number of akinetic/dyskinetic segments before surgery
was 7 (2.25) and was reduced to a median of 3 (1.5) at
3 months after myoblast implant (P=0.01). The WMSI
(mean and SEM) was 1.73±0.14 at baseline versus
1.25±0.07 at 3 months (P=0.0001) (Table 2). To try to
better differentiate the potential benefit on cardiac
function due to myoblast transplant and to revasculariz-
ation, we examined the improvement in the WMSI in
those segments in which myoblasts had been implanted
along with revascularization and in those that did not
receive cells but only revascularization. Although there
was a significant reduction in the WMSI for segments
treated and non-treated, these differences were greater
in the case of treated areas (Tables 2 and 3). The median
NYHA class was reduced at 3 month follow-up from
3 baseline to 2, 3 months post surgery (P=0.007).
Myocardial perfusion and viability studies
In seven out of 12 patients both 18F-FDG and 13N-
ammonia PET were performed before surgery (1–5 days)
and 3 months after surgery. Before surgery the mean
glucose uptake value was 0.158±0.026 µmol g−1 min−1 for
the whole myocardium and 3 months post surgery was
0.270±0.008 µmol g−1 min−1 (P=0.012). When we analysed
the area of necrotic tissue due to myocardial infarction
(infarct area) there was a significant increase in 18F-FDG
uptake suggesting increased myocardial viability in the
infarct area (Table 4). Although an increase in 13N-
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Fig. 1 Left ventricular function assessed by analysis of left ventricular
ejection fraction (LVEF) calculated with 2D and ABD echocardiogram.
Results represent mean±SEM. P=0.002 between LVEF baseline and
3 months (2D); P=0.001 between LVEF baseline and 3 months (ABD).
Table 2 Regional function (Wall motion score index)
Baseline 40 days 3 months Pa
Global 1.73±0.14 1.40±0.07 1.25±0.07 0.0001
Treated
segments 2.64±0.13 2.03±0.16 1.64±0.16 0.0001
Untreated
segments 1.29±0.13 1.1±0.06 1.05±0.04 0.02
aP: comparison between WMSI baseline and at 3 months follow-up.
Results represent the mean±SEM.
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ammonia uptake was detected after treatment with
revascularization and myoblast implant, these differ-
ences were not statistically significant either for the
whole myocardium or even when the analysis was
restricted to the infarct area. In Fig. 2A we show the
18F-FDG and 13N-ammonia PET from a representative
patient at baseline and at 3 months post surgery. In
Fig. 2B we show the 18F-FDG and 13N-ammonia PET from
patient number 9 who did not receive skeletal myoblast
due to cell contamination but otherwise underwent the
same surgical procedure and follow-up. Arrowheads
indicate areas with lack of viability.
Discussion
The main findings of our study can be summarized as
follows: (1) Transplantation of autologous skeletal myo-
blast directly into the myocardium in patients undergoing
CABG surgery and with a history of MI is safe and feasible.
(2) Treatment with bypass surgery and myoblast injection
in segments with abnormal WMSI results in both improve-
ment in myocardial contractility (decreased WMSI) and
increased in tissue viability. Differences in WMSI at base-
line and 3 months after treatment are greater when we
consider segments treated with revascularization and
cell implant. (3) Increase uptake of glucose by 18F-FDG
PET is observed in the infarct area implanted with
skeletal myoblast, 3 months post surgery.
The use of stem cells and in particular of skeletal
myoblast for cardiac repair in patients with myocardial
infarction has been an active field of research for the last
few years. It has been demonstrated both in large and
small animal models that these cells engraft, differen-
tiate into skeletal fibers, acquire certain characteristics
of cardiac muscle and contribute to improve cardiac
function and animal survival.16,20,21,23 Very recent
reports in patients with myocardial infarction have
shown that skeletal autologous myoblast can survive
after transplantation and form viable grafts in heavily
scarred human myocardial tissue thus providing a proof of
principle.17,22,31
Although skeletal myoblast can be successfully trans-
planted, the percentage of cells that survive and differ-
entiate into functional tissue is currently unknown and
some reports suggest that it may be lower than 1%.31,32
The implication is that a very large number of cells may
be required for this therapy to work.
The number of cells injected in our patients (200×106
cells were injected subepicardially) was significantly
lower than cells injected in the study from Menasche
et al.33 and similar to the number of cells injected in the
study by Pagani et al. in which engraftment of myoblast
was demonstrated.31 Although, proof of engraftment was
not obtained in our patients, based on these two studies
probably enough cells were injected to obtain a success-
ful engraftment. The increase in 18F-FDG uptake in the
area where cells had been implanted suggest that viable
tissue was present in the area of the infarct where
previously no viable tissue could be detected. In any
case, we cannot directly demonstrate contribution to
contractility of implanted cells.
Although no control patients were included in the
study, contamination of skeletal myoblast in one patient
gave us the opportunity to assessed the effect of CABG on
18F FDG PET. Remarkably, no significant changes were
Table 3 Regional function (Wall motion score index) in each
patient for those segments treated with revascularization
and cells and those treated with revascularization alone
Segments
treated/
non-treated
Baseline WMSI
treated/
non-treated
3 months WMSI
treated/
non-treated
UPN 1 4 3.1 1.75
12 1.08 1
UPN 2 7 3.1 1.4
9 1.81 1.18
UPN 3 4 3.2 1
12 1.16 1
UPN 4 3 3 2
13 1 1
UPN 5 5 3.3 2
11 1.5 1.16
UPN 6 6 3.2 2.2
10 1.22 1
UPN 7 4 3.1 1.8
12 1.3 1
UPN 8 5 3.3 2
11 1.6 1.16
UPN 9 — — —
UPN 10 — — —
UPN 11 5 3.4 2.4
11 1.18 1
UPN 12 7 3.57 2.8
9 1.12 1
Table 4 13N-ammonia (ml g−1 min−1) and 18F-FDG (µmol g−1 min−1) positron emission tomography scan (PET)a
Baseline 3 months P
Global 18F FDG 0.158±0.026 0.270±0.008 0.012
13N ammonia 0.47±0.05 0.5±0.03 0.309
Infarct 18F FDG 0.126±0.022 0.231±0.011 0.010
13N ammonia 0.36±0.04 0.39±0.01 0.537
Non infarct 18F FDG 0.170±0.029 0.284±0.0.013 0.014
13N ammonia 0.59±0.07 0.62±0.06 0.365
aResults represent the mean±SEM.
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Fig. 2 18F-FDG and 13N-ammonia PET. Baseline analysis and 3 months after surgery are represented. (A) Patient 5: a representative example of a patient
with implanted myoblast. (B) Patient 9: no myoblast implant due to sample contamination. Arrows indicate infarct tissue before and after surgery.
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observed 3 months after surgery in patient 9, not receiv-
ing skeletal myoblast (Fig. 2B). The results by no means
demonstrate that the increase in glucose uptake is due to
skeletal myoblast but is an interesting finding that sup-
ports the use of PET scan for monitoring viability of
implanted cells in future studies.
Beside engraftment, proving that implanted cells con-
tribute to cardiac function is of paramount relevance
before this type of therapy can be applied clinically. Left
ventricular cardiac function improvement has been well
documented in animal models of MI7,21,34 despite the lack
of understanding of the mechanism responsible for the
effect.35 Although some studies have suggested that
myoblast acquire certain characteristics of cardiac
muscle after transplantation into the myocardium
(presence of cardiac specific MHC and connexin 43)18,21
and that at least in vitro, skeletal fibers and cardiac
muscle can form electromechanical junctions 36 the over-
whelming evidence suggest that this is not the case and
that skeletal myoblast do not transdifferentiate into
cardiomyocytes.24,37 The elastic properties of implanted
fibers and/or the secretion of certain growth or survival
factors by cells, contributing to remodelling or to recruit-
ment of circulating or local cardiac stem cells have been
implicated as potential mechanisms involved in the
observed benefit of myoblast transplant in animal
studies.35
Unlike animal models, human studies have included
patients subjected to bypass surgery and cell transplant
preventing a clear conclusion as to the benefit derived
from cell transplant. Our patients received both cells and
revascularization to the same area, so the observed
improvement in LVEF and WMSI can be attributed at least
in part to revascularization. The fact that those segments
of the heart treated with cells and revascularization
experienced a greater improvement in WMSI indi-
cates that it is unlikely that the only reason for cardiac
improvement is the CABG surgery. Furthermore, it has
been well demonstrated that re-perfusion of non viable
and fibrotic tissue as a result of MI does not improve
cardiac function or viability.38
The lack of glucose uptake before surgery rules out
that the tissue where the cells were implanted might
have been hibernating tissue that could have become
viable as a consequence of revascularization. In any case,
to demonstrate that skeletal myoblast are responsible for
improvement in cardiac function we will need to trans-
plant the cells without any further therapy and currently
this would not be ethical unless cells could be applied by
percutaneous injection.
An interesting finding in our patients is the lack of
cardiac arrythmias observed, which is in contrast with
recent studies31,33 in which four out of 10 patients with
old MI treated with CABG and intramyocardial injection
of skeletal myoblast required implantation of automatic
internal cardioverter-defibrillator.33 The cause of arryth-
mias is at present unknown but it may be related to
reentry electrical circuits due to the fact that skeletal
myoblast do not established gap junctions with
cardiomyocytes,24 the number and/or volume of cells
implanted or other currently unknown mechanisms. We
cannot rule out that the low incidence of arrhythmias in
our patients is not due to the revascularization of the
infarct area or even to patient selection as the baseline
LVEF was better in our study that in either of the previous
studies.31,33 In a very recent study, the finding that
skeletal myoblast do not establish gap junctions with
cardiomyocytes has been hypothesized as a mechanism
to prevent the generation of deleterious extrasystoles.37
Unlike other studies, our patients received myoblast
cultured without fetal bovine serum. The use of xeno-
geneic proteins could be associated with an immune
reaction and inflammation although only very limited
signs of inflammation have been described in patients
treated with skeletal myoblast.31 Whether the use of FCS
serum could induce some inflammation that favours the
incidence of arrythmias is currently unknown. Similar
results have been described by the group of Trainini et al.
using autologous serum for in vitro expansion of skeletal
myoblast in four patients undergoing CABG surgery and
myoblast transplant (personal communication).
Other ways of transplanting stem cells as well as
different sources of stem cells other than skeletal myo-
blast have been explored in patients.11–13,39 Results are
challenging and cardiac function improvement have been
suggested both in patients with acute and non acute
myocardial infarction indicating that cardiac repair may
be a reasonable goal within a few years, yet this field is
just at its infancy.
In conclusion, our results suggest that cell transplan-
tation with bypass surgery is associated with improve-
ment in cardiac function, increased tissue viability and
lack of side effects thus resulting in a promising therapy
for patients with heart failure. We believed that these
results warrant further clinical research including
randomized studies.
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